Search

Displaying results 1761 - 1770 of 5898 in total
  1. Drug

    Tocofersolan

    go.drugbank.com/drugs/DB11635
    Approved

    In addition to the above, tocofersolan has been studied as a promising application as an absorption enhancer in drug delivery [MSDS]. … Cholestasis is the reduction or stoppage of bile flow, either to impaired secretion by _hepatocytes_ (liver cells) or obstruction [L2374], [L2375].

  2. Drug

    Donidalorsen

    go.drugbank.com/drugs/DB18751
    ApprovedInvestigational

    [L53788] Donidalorsen was approved by the FDA in August 2025 for prophylactic use to prevent HAE attacks.[L53783,L53788] It is the first RNA-targeted therapy approved for HAE.[L53783]

    Synonyms: -(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL), DNA, D((2'-O-(2-METHOXYETHYL))M5RU-SP-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RA-SP-G-SP-T-SP-M5C-SP-T-SP-M5C-SP-T-SP-T-SP-G-SP-G-SP-M5C-SP
  3. Drug

    Darifenacin

    go.drugbank.com/drugs/DB00496
    ApprovedInvestigational

    This block reduces the urgency to urinate and so it should not be used in people with urinary retention. … Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions.

  4. Drug

    Belatacept

    go.drugbank.com/drugs/DB06681
    ApprovedInvestigational

    The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. … Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each.

  5. Drug

    Levocarnitine

    go.drugbank.com/drugs/DB00583
    ApprovedInvestigational

    It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.

    Products: LEVOCARNITINA MYLAN GENERICS
  6. Drug

    NAV 1800

    go.drugbank.com/drugs/DB05437
    Experimental

    RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal cancer.

  7. Drug

    Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media

    go.drugbank.com/drugs/DB15728
    Experimental

    One of these companies, Aspire, has created their own product, ACT-20 Conditioned Medium as a product for testing. … In comparison to bone-marrow derived MSCs, these cells are more resilient, easier to extract, and generally regarded as less immunogenic.

  8. Drug

    Gemcitabine

    go.drugbank.com/drugs/DB00441
    ApprovedInvestigational

    [A233135] Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. … [L32960] The structure, metabolism, and mechanism of action of gemcitabine are similar to [cytarabine], but gemcitabine has a wider spectrum of antitumour activity.

    Synonyms: 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-oneProducts: GEMCITABINA MYLAN GENERICS, UNIGEM-Gemcitabine 38mg/mL concentrate for solution for Infusion
  9. Drug

    Human cytomegalovirus immune globulin

    go.drugbank.com/drugs/DB13886
    ApprovedInvestigational

    Cytomegalovirus (CMV) may lead to a wide spectrum of infection in immunocompetent hosts. … The seroprevalence of antibodies in adults ranges from 40-100 % with an inverse correlation to socioeconomic status.

  10. Drug

    Maraviroc

    go.drugbank.com/drugs/DB04835
    ApprovedInvestigational

    Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the

    Categories: CCR5 Co-receptor Antagonist